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Abstract
Background: The outer membrane protein M35 is a conserved porin of type 1 strains of the
respiratory pathogen Moraxella catarrhalis. It was previously shown that M35 is involved in the
uptake of essential nutrients required for bacterial growth and for nasal colonization in mice. The
aim of this study was (i) to characterize the potential roles of M35 in the host-pathogen interactions
considering the known multifunctionality of porins and (ii) to characterize the degree of
conservation in the phylogenetic older subpopulation (type 2) of M. catarrhalis.
Results: Isogenic m35 mutants of the type 1 strains O35E, 300 and 415 were tested for their
antimicrobial susceptibility against 15 different agents. Differences in the MIC (Minimum Inhibitory
Concentration) between wild-type and mutant strains were found for eight antibiotics. For
ampicillin and amoxicillin, we observed a statistically significant 2.5 to 2.9-fold MIC increase (p <
0.03) in the m35 mutants. Immunoblot analysis demonstrated that human saliva contains anti-M35
IgA. Wild-type strains and their respective m35 mutants were indistinguishable with respect to the
phenotypes of autoagglutination, serum resistance, iron acquisition from human lactoferrin,
adherence to and invasion of respiratory tract epithelial cells, and proinflammatory stimulation of
human monocytes. DNA sequencing of m35 from the phylogenetic subpopulation type 2 strain 287
revealed 94.2% and 92.8% identity on the DNA and amino acid levels, respectively, in comparison
with type 1 strains.
Conclusion: The increase in MIC for ampicillin and amoxicillin, respectively, in the M35-deficient
mutants indicates that this porin affects the outer membrane permeability for aminopenicillins in a
clinically relevant manner. The presence of IgA antibodies in healthy human donors indicates that
M35 is expressed in vivo and recognized as a mucosal antigen by the human host. However,
immunoblot analysis of human saliva suggests the possibility of antigenic variation of
immunoreactive epitopes, which warrants further analysis before M35 can be considered a
potential vaccine candidate.
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Background
Moraxella catarrhalis is an exclusively human, mucosal res-
piratory tract commensal and pathogen causing between
5% [1] and 20% of cases of acute otitis media in children
[2] across all regions of the world. The recent introduction
of routine infant immunization with pneumococcal con-
jugate vaccines has - in some studies [3] - led to a substan-
tial increase in otitis media caused by M. catarrhalis [3]. It
is thus a major cause of the most common bacterial infec-
tion in children requiring medical attention. M. catarrhalis
also triggers approximately 10% acute exacerbations of
chronic obstructive pulmonary disease (COPD) in adults
[4]
In our attempts to identify cold shock regulated outer
membrane proteins (OMP) of M. catarrhalis [5] we inves-
tigated a recently described OMP called M35. We found
no evidence of cold shock regulation, but the construction
of an isogenic mutant lacking the expression of a currently
incompletely described OMP of M. catarrhalis provided us
with the opportunity to conduct a phenotypic analysis of
the function of M35. Meanwhile, in an elegant series of
experiments, Easton and co-workers [6] demonstrated
that M35 is a typical Gram-negative OM porin, which also
is essential for short-term nasal colonization of mice.
Importantly, porins of Gram-negative bacteria not only
assure bacterial homeostasis by acting as transport chan-
nels, but are also known to afford virulence mechanisms
such as adhesion, invasion [7-11], and pro-inflammatory
stimulation. [11-17]. In addition, porins are often
involved in antimicrobial resistance [18-26]. Porins of M.
catarrhalis have received little attention in the scientific lit-
erature. Gotho et al. described the permeability for beta-
lactam antibiotics across the OM of M. catarrhalis suggest-
ing that porins may be involved [27]. Lafontaine et al
investigated the porin-like OMP CD, which acts as an
adhesin on lung cells [7]. Thus, M35 is currently the only
well characterized porin of M. catarrhalis [6,28].
The aims of the present study were (i) to provide an over-
view of phenotypic differences between the strains O35E,
300 and 415 and their respective isogenic m35 mutants,
(ii) to investigate whether M35 is a human mucosal anti-
gen and thus a potential vaccine candidate, (iii) to evalu-
ate the role of M35 in the susceptibility of M. catarrhalis to
various classes of antimicrobial agents, and (iv) to provide
the DNA sequence m35 of strain 287, which is a represent-
ative of the phylogenetically older major lineage (type 2)
of M. catarrhalis [29].
Methods
Bacterial strains and culture conditions
The M. catarrhalis strains and their isogenic m35 mutants
used in this study are listed in Table 1. All strains were cul-
tured at 37°C and 150-200 rpm in brain heart infusion
(BHI) broth (Difco, Detroit, MI) or on BHI agar plates in
an atmosphere containing 5% CO2. Media were supple-
mented with kanamycin (20 μg/ml) for culturing of the
mutants. To investigate growth under different osmotic
conditions, strains were cultured in BHI broth overnight
at 37°C and 150 rpm. One ml of overnight culture was
diluted 1:100 in fresh BHI supplemented with 0.25 M, 0.5
M or 1.0 M NaCl, respectively, and incubated at 37°C and
150 rpm. During cultivation to the stationary phase cell
density was measured at OD600. The effect of exposure to
different acidic environments was measured by growing
bacteria in BHI broth overnight, harvesting and resus-
pending them in 20 mM Na2HPO4/NaH2PO4, 1 mM
MgCl2, 25 mM L-arginine adjusted to pH 4.0, pH 5.0, pH
6.0, or pH 7.0, respectively. Suspensions were incubated
for 2 h and 4 h, respectively, at 37°C, and the number of
viable bacteria was quantified by plating of serial dilu-
tions. Iron utilization experiments were performed by a
disk feeding assay applying 5 μl of iron-saturated human
lactoferrin (10 mg/ml) to sterile filter disks [30]. BHI agar
plates were previously iron depleted by adding deferox-
amine mesylate (Desferal, Novartis, Basel, Switzerland) to
a final concentration of 30 μM and incubated at 4°C over-
night before use. Escherichia coli DH5α was grown on
Luria-Bertani (LB) agar plates or in LB broth.
DNA methods
Plasmids were isolated using the Wizard Plus SV Miniprep
DNA purification system (Promega Corp., Madison, Wis.)
DH5α was transformed as described previously [31].
Restriction enzymes were purchased from New England
Table 1: Bacterial strains used in this study
Strain Description Source or reference
M. catarrhalis O35E middle ear isolate [65]
M. catarrhalis O35E.m35 isogenic mutant strain, kanR this study
M. catarrhalis 300 nasopharyngeal isolate from child [35]
M. catarrhalis 300.m35E isogenic mutant strain, kanR this study
M. catarrhalis 415 nasopharyngeal isolate from child [35]
M. catarrhalis 415.m35
M. catarrhalis 287
isogenic mutant strain, kanR
nasopharyngeal isolate from child
this study
[35]
Escherichial coli DH5α Host strain for plasmid constructs [66]BMC Microbiology 2009, 9:188 http://www.biomedcentral.com/1471-2180/9/188
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Biolabs, Inc., Beverly, MA. Electrocompetent M. catarrhalis
was prepared and DNA was electroporated as described
[32]. DNA sequencing was performed by using an ABI
PRISM 310 genetic analyzer (PE Biosystems, Rotkreuz,
Switzerland) with the Big Dye Terminator cycle sequenc-
ing ready reaction kit (PE Biosystems, Rotkreuz, Switzer-
land). Sequences were analyzed with the Lasergene
software (DNASTAR Inc., Madison, WI). For sequencing
of m35 of strain 287, DNA was amplified using the prim-
ers  m35B5 (5'-TCGATACCAGAACACTACCTAAGC-3'),
m35F2 (5' -GTCTGAGGGCAAGGTAGGCG-3'), m35RMJ1
(5' -CGTAGCAGTTTTCATCTCACCAC 3'), m35F3 (5'-
CTTGCTCTAGCAACCGCAG-3'),  m35R3 (5'-GCAAGAC-
CTAGGTAAGTATC-3') and m35FMJ4 (5'-TGCGTGCAT-
GGGTCGTGA-3').
Construction of the isogenic mutants O35E.m35, 300.m35 
and 415.m35
Part of the m35 gene of the strains O35E, 300 and 415,
respectively, was amplified using forward primer m35F3
(5'-CTTGCTCTAGCAACCGCAG-3') and reverse primer
m35B5 (5'-TCGATACCAGAACACTACCTAAGC-3'). PCR
products were ligated into the BamHI restriction site of
pGEM-T-Easy pUC4K (Promega, Madison, USA). The
kanamycin cassette was ligated into the AvrII restriction
site of the m35 insert. The resulting construct, Δm35:kan,
was used for electroporation of the competent strains
O35E, 300 and 415, respectively. Transformants were
selected on BHI agar plates containing 20 μg/ml of kan-
amycin. Insertional inactivation of m35 was confirmed by
PCR analysis, sequencing, Southern blot analysis (data
not shown) and immunoblotting (figure 1).
Preparation of OMP
OMP were prepared by the EDTA buffer method as
described [33]. Bacteria were harvested from a stationary
phase culture, resuspended in EDTA buffer (0.05 M
Na2HPO4, 0.15 M NaCl, 0.01 M EDTA, ph 7.4), homoge-
nized and incubated at 55°C at 300 rpm for 1 h. Cells and
cell debris were eliminated by centrifugation at 10,000 ×
g for 15 min at 4°C. Finally, OMP were collected by ultra-
centrifugation at 100.00 × g for 2 h at 4°C.
(A) SDS PAGE of M. catarrhalis OMP of the strains O35E, 300 and 415 together with their respective m35 knock-out mutants Figure 1
(A) SDS PAGE of M. catarrhalis OMP of the strains O35E, 300 and 415 together with their respective m35 
knock-out mutants. Black triangles show the position of the M35 protein band at 36 kDa. White triangles show the position 
of the 40 kDa protein. The spectra display the intensity of each protein band determined by the AlphaEaseFC® software. Light 
lines show the wild-type strain, dark lines show the respective M35 mutant strains. (B) Western Blot analysis for human sali-
vary IgA against M35 of the strains O35E, 300 and 415 from seven healthy donors. The isogenic m35 mutants were included as 
negative controls.BMC Microbiology 2009, 9:188 http://www.biomedcentral.com/1471-2180/9/188
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2D-Gel electrophoresis and MALDI-TOF
Analysis of M35 and other OMP spots of strain O35E was
performed a described previously [34], except for the pre-
cipitation of the OMP, which was omitted.
SDS-PAGE gel electrophoresis and immunoblot for 
detection of human anti-M35 IgA
Samples were resolved by SDS-PAGE using a 7.5% poly-
acrylamide gel. Band intensity was quantified using the
AlphaEaseFC® program from Inotech, Inc. Antibody detec-
tion was performed by Western blot analysis. Proteins
were transferred to polyvinylidene difluoride (PVDF)
membranes (Immobilon-P; Millipore Corp., Bedford,
MA). IgA binding was detected using human saliva sam-
ples as primary antibody source and goat anti-human IgA,
respectively, labeled with horseradish peroxidase
(SIGMA) as secondary antibody. Super Signal West Pico
Chemiluminescent Substrate (Pierce Chemical Co., Rock-
ford, IL) was used for detection of antibody binding.
Unstimulated human saliva was collected from healthy
volunteers using Salivette sponges® (Sarstedt, Nümbrecht,
Germany), centrifuged for 5 minutes at 2000 rpm and
stored at -20°C. All volunteers were laboratory researchers
and provided oral informed consent. Sampling of saliva
from healthy volunteers was approved by the local ethics
committee.
Antimicrobial resistance testing
The minimum inhibitory concentrations (MIC) of peni-
cillin, ampicillin, amoxicillin, amoxicillin-clavulanate,
cefuroxime, ceftriaxone, imipenem, meropenem, erythro-
mycin, doxycycline, gentamicin, vancomycin, cipro-
floxacin, levofloxacin, and moxifloxacin were determined
by E-test® (AB Biodisk, Sweden) according to the manufac-
turer's instructions.
Autoagglutination and serum bactericidal assay
Overnight cultures were resuspended in PBS and adjusted
to an OD600 of 2.0 in glass tubes. OD600 of the superna-
tants were determined after 15 and 60 minutes, respec-
tively. Serum bactericidal assay were performed as
previously reported [35].
Human cell lines and growth conditions
Chang conjunctival cells and A549 lung cells were main-
tained in Eagle's minimal essential medium (Invitrogen,
Basel, Switzerland) supplemented with 10% of heat-inac-
tivated fetal calf serum, 100 units/ml penicillin, 100 μg/
ml streptomycin, and 2 mM L-glutamine at 37°C in 5%
CO2. The THP-1 human monocytic cell line was main-
tained in RPMI 1640 (Lonza, Basel, Switzerland) supple-
mented with 2 mM L-glutamine, 10% heat-inactivated
fetal calf serum, 0.05 mM β-mercaptoethanol, 10 mM
HEPES, 100 units/ml penicillin and 100 μg/ml streptomy-
cin at 37°C in 5% CO2.
Adherence and Invasion assay
The ability of M. catarrhalis to adhere to and invade
human epithelial cells in vitro was measured as described
previously [36]. Adherence and invasion was assessed on
both Chang conjunctival cells and A549 lung cells as
described [36,37]. Each strain was analyzed in triplicate in
each experiment.
Proinflammatory activity of M35 on human monocytes
The pro-inflammatory potential of M. catarrhalis OMP
was described previously [38]. To investigate if M35 is an
important mediator of proinflammatory cytokine release
on the bacterial cell surface, THP-1 cells (1 × 106/ml) were
stimulated with different concentrations (1 × 105/ml, 1 ×
106/ml, or 1 × 107/ml) of heat inactivated strain O35E or
the O35E.m35 mutant and incubated for 18 h at 37°C
and 5% CO2. After incubation, cells were centrifuged for
2 min at 11,800 × g and supernatants were stored at -
80°C. Cytokines were measured using the R&D Systems
DY208 for human CXCL8/IL-8 and R&D Systems DY210
for human TNFα/TNFSF1A (R&D, Minneapolis, USA),
respectively.
Statistical analysis
Comparison of several test series was evaluated by analy-
sis of variance (ANOVA). The significance of differences
between treatment and control groups was determined
using the two-tailed t-test. P < 0.05 was considered as sta-
tistically significant. Each value represents the mean ± one
standard deviation of at least three independent experi-
ments performed in triplicate.
Results
In vitro growth of m35 mutants
Standard growth curves of the three wild-type/mutant
pairs in BHI broth revealed no difference in growth veloc-
ity measured as broth density at OD600 (data not shown).
Because porins are frequently involved in stress responses
of bacteria against changes in osmolarity or pH [39-41],
we investigated the wild-type/mutant pairs with respect to
growth at various osmotic (supplementation of BHI with
0.25, 0.5 and 1 M NaCl) and acidic (pH 4-7) conditions
(figure 2). Again, wild-type strains and their respective
mutants behaved identically.
M35 knockout is not associated with upregulation of a 40 
kDa OMP
Easton et al. [6] described the upregulation of a 40 kDa
protein in one of their isogenic m35 mutants. In order to
confirm this observation, we compared Coomassie-blue
stained OMP profiles of our three strains with their respec-
tive  m35  mutants, but failed to detect any discernible
upregulation of other OMP as determined by measuring
protein band intensities (figure 1A). Thus, removal of
M35 does not appear to affect the OMP compositionBMC Microbiology 2009, 9:188 http://www.biomedcentral.com/1471-2180/9/188
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Growth of M. catarrhalis O35E and its isogenic m35 mutant under acidic (A) and osmotic (B) stress Figure 2
Growth of M. catarrhalis O35E and its isogenic m35 mutant under acidic (A) and osmotic (B) stress. (A) The 
effect of exposure to different acidic conditions was measured by growing bacteria in BHI adjusted to pH 4.0, pH 5.0, pH 6.0, 
or pH 7.0, respectively. Suspensions were incubated for 2 h and 4 h, respectively, and the number of viable bacteria was quan-
tified by plating on BHI agar plates. (B) Different osmotic conditions were investigated by culturing bacteria in BHI supple-
mented with 0.25 M, 0.5 M or 1.0 M NaCl. During cultivation to the stationary phase bacterial density was measured at OD600.BMC Microbiology 2009, 9:188 http://www.biomedcentral.com/1471-2180/9/188
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when bacteria are grown in BHI. Taken together, the data
presented thus far indicate that M35 is not essential for
growth in vitro and that its removal from the OM does not
otherwise affect the OMP composition.
M35 is expressed in vivo
The human mucosal antibody response to OM compo-
nents of M. catarrhalis has been described in detail [42-
45], but M35 has never been paid specific attention. In
order to search for human antibodies against M35, OMP
of the strains O35E, 300, 415 and their isogenic mutants
were resolved by SDS-PAGE, transferred to PVDF mem-
branes, and incubated with human saliva for detection of
IgA. Western Blot analysis for anti-M35 IgA with 7 differ-
ent donors resulted in antibody signals to all three strains
with the strains 300 and 415 displaying broader immuno-
genicity than O35E (figure 1B). Four of seven donor saliva
contained anti-M35 IgA against strain 300 and 415,
respectively. One donor displayed anti-M35 IgA for all
three strains. OMP of the m35 mutants were used as neg-
ative controls (figure 1B). These data suggest that M.
catarrhalis expresses M35 in vivo and that the mucosa-asso-
ciated lymphoid tissue recognizes M35 as an antigen.
Aminopenicillin susceptibility is mediated by M35
One of the major bacterial strategies for drug resistance is
barrier protection, which limits the intracellular access of
antimicrobial agents [18]. The influx of large, charged
molecules is controlled by porins, which allow passive
penetration of hydrophilic molecules of several classes of
antibiotics [19-21]. Thus, porin-mediated OM permeabil-
ity is expected to affect susceptibility to antimicrobial
agents [18,22]. To investigate this, E-tests were performed
with the mutants O35E.m35, 300.m35, 415.m35 and their
respective wild-type parent strains. There were no differ-
ences in MIC for penicillin G, ceftriaxone, meropenem,
erythromycin, doxycycline, gentamicin, and vancomycin
between wild-type and mutant strains, respectively. For
quinolones (ciprofloxacin, levofloxacin and moxi-
floxacin), cefuroxime and imipenem there was a minor,
but consistent ~1.4-fold increase in the MIC of the
mutants (data not shown). For ampicillin and amoxicil-
lin, however, there was a statistically significant increase
in the MIC of the mutants (2.5 to 2.9-fold) in comparison
with their respective wild-types (figure 3A/B) (p = 0.003-
0.023). Interestingly, at an approximately 10-fold lower
level, this was also found for amoxicillin-clavulanate (fig-
ure 3C).
Expression of M35 and putative virulence traits of M. 
catarrhalis
The capacity to autoagglutinate is mediated by hemagglu-
tinin (also called Moraxella IgD-binding protein) [46], but
some hemagglutinin knock-out mutants still autoaggluti-
nate (unpublished data). Thus, we investigated whether
the absence of M35 affected autoagglutination, but failed
to identify any difference between strain O35E and
O35E.m35 (data not shown). Similarly, resistance of M.
catarrhalis  to human complement, which is associated
with disease-causing isolates [47-49] and which requires
expression of several OMP [37,50-52], was not impaired
by the lack of M35 (data not shown). Growth of M.
catarrhalis in vivo is dependent on the ability to acquire
iron from the human host by retrieving Fe3+ from iron-
containing host proteins by a number of specific binding
and uptake systems [30,53-59]. Because of its abundance
on mucosal surfaces, we chose to investigate the ability of
the m35 mutant to use iron bound to human lactoferrin
using a standard disk feeding assay on iron depleted BHI
agar plates [30]. The experiment resulted in no differences
in growth between the three m35  mutants and their
respective wild-type parents (data not shown).
Adherence and invasion of the m35 mutant
The abilities of a pathogen to adhere to and invade epithe-
lial host cells, respectively, are major virulence factors.
Adhesins and invasins usually are OMP [5,36,60,61],
some of which also act as porins [7-11]. To investigate if
M35 mediates adherence and invasion assays were per-
formed on Chang conjunctival cells as well as on A549
lung cells. Adherence of the O35E.m35 mutant was as effi-
cient as that of its wild-type parent strain (figures 4A/B).
Similarly, no differences were found for the capacity to
invade these cell types (figures 4C/D) in gentamicin pro-
tection assays.
Proinflammatory activity of M35 on human monocytes
Proinflammatory activity is typically induced by OMP,
lipopolysaccharide or lipoteichoic acids. Porins have also
been described to induce proinflammatory cascades by
activating innate immune receptors mediating the expres-
sion of several chemokines and cytokines [11-17]. We
investigated M35 with regard to its proinflammatory
effect on human monocytes. THP-1 cells were stimulated
with strain O35E or its O35E.m35 mutant overnight and
cytokine release in the supernatant was measured by
determining the concentrations of IL-8 and TNFα by
ELISA. There was no difference in the release of IL-8 and
TNFα, respectively, between wild-type and mutant (data
not shown).
M35 sequence analysis of type 2 strain 287
M35 is nearly 100% conserved among type 1 strains of M.
catarrhalis [28]. To determine if this is also true for the
other major phylogenetic subpopulations of M. catarrha-
lis, m35 of type 2 strain 287 was sequenced and analyzed
by bioinformatics. In comparison with type 1 strain
O35E, there was a divergence of 5.8% at the DNA level
consisting mainly of point mutations (figure 5). Unex-
pectedly, these DNA mutations lead to an even greaterBMC Microbiology 2009, 9:188 http://www.biomedcentral.com/1471-2180/9/188
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E-tests of the strains O35E, 300 and 415 and their respective isogenic m35 mutants with ampicillin (A), amoxicillin (B) and  amocixillin-clavulanate (C) Figure 3
E-tests of the strains O35E, 300 and 415 and their respective isogenic m35 mutants with ampicillin (A), amoxi-
cillin (B) and amocixillin-clavulanate (C). Bacteria were cultured on agar plates together with E-test strips overnight. Bars 
show the minimum inhibitory concentration (MIC) for each antibiotic. Data are presented as means ± 1 SD (n = 3). * p < 0.05 
for wild-type vs. respective mutant.BMC Microbiology 2009, 9:188 http://www.biomedcentral.com/1471-2180/9/188
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divergence of 6.1% at the amino acid sequence level (fig-
ure 6). This corresponds to a substantial number of mis-
sense mutations.
Discussion
Porins are essential components of the gram-negative
outer membrane and contribute to nutrient transport,
antimicrobial resistance, response to osmostress and
other processes, which are essential for bacterial homeos-
tasis. M35 is the first functionally characterized OM porin
of M. catarrhalis [28] and as of today all isolates examined
carry a highly conserved m35 gene on their chromosome.
This may indicate that strains not expressing M35 are not
viable in vivo, but the only evidence in support of this
hypothesis is the observation that a m35 mutant was una-
ble to colonize the nasal mucosa of mice [6], which are
not a natural host species for M. catarrhalis.
Our observation that healthy humans have mucosal IgA
directed against M35 indicates that this protein is
expressed in vivo. However, the fact that some salivary
samples did not recognize all three M35 proteins tested
suggests that either (i) antigenic variation occurs at immu-
noreactive, surface exposed epitopes, or (ii) it is a weak
antigen and some individuals lose or never acquire anti-
M35 IgA, or (iii) some isolates lack expression of M35 in
vivo. If the latter were the case, screening of large collec-
tions of clinical M. catarrhalis isolates should identify
strains either lacking a m35 gene or isolates carrying silent
genes. The answer to this question is of clinical relevance,
because our data indicate that the absence of M35 is a pre-
viously unknown mechanism of aminopenicillin resist-
ance in M. catarrhalis. This effect could occur in vivo by
alterations in porin expression to prevent antibiotic
influx, which is a well known mechanism of resistance in
other pathogens [18,22], and which often is associated
with the expression of degradative enzymes to confer high
level resistance [23,24]. The specificity of M35 for ami-
nopenicillins could be explained by an effect Bezrukov et
al described for OmpF of E. coli. They found that the
Adherence to Chang conjunctival cells (A) and A549 lung cells (B) and invasion into Chang cells (C) and A549 cells (D) by M.  catarrhalis O35E and its isogenic knock-out mutant O35E Figure 4
Adherence to Chang conjunctival cells (A) and A549 lung cells (B) and invasion into Chang cells (C) and A549 
cells (D) by M. catarrhalis O35E and its isogenic knock-out mutant O35E. m35. The cells were infected and, after 30 
min for adherence and 3 h for invasion, total cell-associated bacteria or intracellular bacteria, respectively, were quantitated by 
dilution plating. Data are represented as means ± 1 SD (n = 3) of at least three separate experiments.BMC Microbiology 2009, 9:188 http://www.biomedcentral.com/1471-2180/9/188
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M35 gene DNA sequence of type 1 strain O35E compared with type 2 strain 287 Figure 5
M35 gene DNA sequence of type 1 strain O35E compared with type 2 strain 287. The red squares indicate diverse 
nucleotides between the two strains.BMC Microbiology 2009, 9:188 http://www.biomedcentral.com/1471-2180/9/188
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nature and position of specific charges on both the antibi-
otic molecule and the porin play a major role in these
interactions [25,26]. Strong binding to the pore correlates
with high diffusion rates whereas weak binding is associ-
ated with reduced diffusion. As of today, the only known
mechanism of aminopenicillin resistance in M. catarrhalis
is the expression of one of three chromosomally encoded
BRO betalactamases, which are detectable in greater than
90% of clinical isolates [62] and explain the fact that the
MIC for amoxicillin-clavulanate in our experiments was at
least 10-fold lower than the MIC for amoxicillin. This
finding indicates that clavulanate penetrates the OM by
ways other than M35. It also demonstrates that, in the
presence of clavulanate, the reduced amount of ami-
nopenicillins still penetrating the OM in m35 mutants suf-
fices to inhibit growth. Thus, it appears that clavulanate
inhibits essentially all betalactamase activity available and
that naturally occurring isolates lacking M35 would not
Deduced M35 amino acid sequence of type 1 strain O35E compared with type 2 strain 287 Figure 6
Deduced M35 amino acid sequence of type 1 strain O35E compared with type 2 strain 287. The red squares indi-
cate diverse amino acids between the two strains.BMC Microbiology 2009, 9:188 http://www.biomedcentral.com/1471-2180/9/188
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currently pose a substantial therapeutic problem in
patients treated with betalactamase-resistant betalactams.
However, standard dose or high dose amoxicillin still is
the therapeutic standard for antimicrobial therapy of
acute otitis media. Based on our data (figure 3), currently
accepted pharmakinetic/pharmcodynamic (PK/PD)
breakpoints for resistance against standard dose (≥ 1.0 μg/
ml) or high dose amoxicillin (≥ 8 μg/ml), respectively,
[63] thus predict that isolates lacking functional M35 may
display clinically relevant aminopenicillin resistance. This
is particularly relevant for the treatment of acute otitis
media. Drug concentrations reached in the middle ear
cavity are low in comparison with serum concentrations
[64] and treatment failure is typically caused by insuffi-
cient drug concentrations in the middle ear fluid [64]. The
list of betalactam antibiotics tested in this study is not
exhaustive and it is conceivable that other drugs may also
be affected by m35 mutations. Thus, further studies are
needed to explore the potential impact of m35 mutants on
antimicrobial treatment failures.
Multiple phenotypic tests that we carried out with three
wild-type/mutant pairs failed to uncover an additional
functions attributable to M35. None of these results is par-
ticularly surprising. The strength of these "negative" data
lies precisely in the fact that we did not study one, but
three different isolates and their respective mutants,
which, taken together, provide firm evidence that M35 is
not involved these various phenotypes in vitro. The analy-
sis of three different wild-type/mutant pairs also lead to
the conclusion that knocking-out m35 does not necessar-
ily upregulate expression of a 40 kDa OMP as stated by
Easton et al (figure 1A). Because these authors used a dif-
ferent strain, it is conceivable that they observed a strain-
specific phenomenon, which does not represent the entire
species. Finally, we sequenced m35 of a strain belonging
to the phylogenetically old, second subpopulation of M.
catarrhalis [29], which differs from the younger subpopu-
lation by a considerably larger genetic diversity [29].
Indeed, we found a substantial number of sequence devi-
ations, which, interestingly, were even greater at the
amino acid level than at the DNA level. It is thus conceiv-
able that type 2 strains exhibit functional and/or antigenic
differences with respect to M35, which warrant further
investigation.
Conclusion
The significant increases in MIC for ampicillin and amox-
icillin of the m35 mutants indicate that the OM porin M35
is involved in the uptake of aminopenicillins. This is a
previously unknown mechanism of resistance in M.
catarrhalis. It remains to be elucidated whether naturally
occurring, disease causing strains of M. catarrhalis devoid
of functional M35 exist, and whether they may contribute
to clinical treatment failure. The fact that normal human
saliva contains anti-IgA indicates that M35 is expressed in
vivo, but that antigenic variation may be greater than pre-
viously appreciated. Thus, further studies are needed
before M35 can be considered a potential vaccine candi-
date against M. catarrhalis.
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